New blood pressure pill enters human safety trials

NCT ID NCT07254481

Recruiting now Disease control Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 06, 2026 · Updated 21 times

Summary

This early-stage study tests a new tablet called VB19055 in 86 healthy Chinese adults to see if it is safe and how the body processes it. The goal is to gather initial safety data for a potential new high blood pressure treatment. Participants will be randomly assigned to receive the drug or a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hangzhou First People's Hospital
RECRUITING

Hangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITING

Shanghai, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HYPERTENSION